- Jul 2018
-
europepmc.org europepmc.org
-
On 2014 Dec 21, Massimiliano Tognolini commented:
Dear Colleagues, I do not want to discuss the connection between Alzheimer’s disease and EphA4 when demonstrated with biological tools (siRNA, mutant mice, peptides, antibodies…) in vitro or in vivo. However, major concerns raises when rhynchophylline was used. Its pharmacological characterization was very weak and flaws were present. More details are reported as comment of original paper: http://www.ncbi.nlm.nih.gov/pubmed/?term=epha4+ameliorates
This comment, imported by Hypothesis from PubMed Commons, is licensed under CC BY.
-
- Feb 2018
-
europepmc.org europepmc.org
-
On 2014 Dec 21, Massimiliano Tognolini commented:
Dear Colleagues, I do not want to discuss the connection between Alzheimer’s disease and EphA4 when demonstrated with biological tools (siRNA, mutant mice, peptides, antibodies…) in vitro or in vivo. However, major concerns raises when rhynchophylline was used. Its pharmacological characterization was very weak and flaws were present. More details are reported as comment of original paper: http://www.ncbi.nlm.nih.gov/pubmed/?term=epha4+ameliorates
This comment, imported by Hypothesis from PubMed Commons, is licensed under CC BY.
-